Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803

Trial Profile

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs ALT 803 (Primary) ; Natural killer cell therapy (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colon cancer; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Mar 2017 Planned number of patients changed from 27 to 54.
    • 30 Mar 2017 Planned initiation date changed from 1 Oct 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top